TENX completes Phase 3 trial enrollment, extends cash runway to Q1 2028 on warrant proceeds

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~1 min read

Key Changes

• high

  Achieved target enrollment of 230 patients in LEVEL Phase 3 trial in March 2026, a key milestone toward potential commercialization of oral levosimendan for heart failure.

  MD&A: LEVEL trial enrollment milestone verify on EDGAR →
• high

  Extended cash runway from 'through 2027' to 'at least Q1 2028' after receiving $30.5M from warrant exercises in Q1 2026 and $7.9M post-quarter, providing 18+ months of funding visibility.

  MD&A: cash runway guidance verify on EDGAR →
• high

  Filed $300M shelf registration (effective April 2026), enabling future equity or debt offerings to fund development beyond current cash runway as LEVEL and LEVEL-2 trials progress.

  MD&A: shelf registration filing verify on EDGAR →